186 related articles for article (PubMed ID: 37946084)
1. Vitamin B
Kreuzaler P; Inglese P; Ghanate A; Gjelaj E; Wu V; Panina Y; Mendez-Lucas A; MacLachlan C; Patani N; Hubert CB; Huang H; Greenidge G; Rueda OM; Taylor AJ; Karali E; Kazanc E; Spicer A; Dexter A; Lin W; Thompson D; Silva Dos Santos M; Calvani E; Legrave N; Ellis JK; Greenwood W; Green M; Nye E; Still E; ; Barry S; Goodwin RJA; Bruna A; Caldas C; MacRae J; de Carvalho LPS; Poulogiannis G; McMahon G; Takats Z; Bunch J; Yuneva M
Nat Metab; 2023 Nov; 5(11):1870-1886. PubMed ID: 37946084
[TBL] [Abstract][Full Text] [Related]
2. Vitamin B5 Supports Oncogenic Metabolism in MYC-Driven Breast Cancer.
Cancer Discov; 2024 Jan; 14(1):15. PubMed ID: 37991361
[TBL] [Abstract][Full Text] [Related]
3. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
4. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
5. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
[TBL] [Abstract][Full Text] [Related]
7. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state.
Poli V; Fagnocchi L; Fasciani A; Cherubini A; Mazzoleni S; Ferrillo S; Miluzio A; Gaudioso G; Vaira V; Turdo A; Gaggianesi M; Chinnici A; Lipari E; Bicciato S; Bosari S; Todaro M; Zippo A
Nat Commun; 2018 Mar; 9(1):1024. PubMed ID: 29523784
[TBL] [Abstract][Full Text] [Related]
8. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
Chen Z; Wang Y; Warden C; Chen S
J Steroid Biochem Mol Biol; 2015 May; 149():118-27. PubMed ID: 25683269
[TBL] [Abstract][Full Text] [Related]
9. Major involvement of Na(+) -dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells.
Uchida Y; Ito K; Ohtsuki S; Kubo Y; Suzuki T; Terasaki T
J Neurochem; 2015 Jul; 134(1):97-112. PubMed ID: 25809983
[TBL] [Abstract][Full Text] [Related]
10. TEAD activity is restrained by MYC and stratifies human breast cancer subtypes.
Elster D; Jaenicke LA; Eilers M; von Eyss B
Cell Cycle; 2016 Oct; 15(19):2551-2556. PubMed ID: 27433809
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic protein MTBP interacts with MYC to promote tumorigenesis.
Grieb BC; Gramling MW; Arrate MP; Chen X; Beauparlant SL; Haines DS; Xiao H; Eischen CM
Cancer Res; 2014 Jul; 74(13):3591-602. PubMed ID: 24786788
[TBL] [Abstract][Full Text] [Related]
12. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
[TBL] [Abstract][Full Text] [Related]
13. mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer.
Sodi VL; Khaku S; Krutilina R; Schwab LP; Vocadlo DJ; Seagroves TN; Reginato MJ
Mol Cancer Res; 2015 May; 13(5):923-33. PubMed ID: 25636967
[TBL] [Abstract][Full Text] [Related]
14. Notch, Myc and breast cancer.
Efstratiadis A; Szabolcs M; Klinakis A
Cell Cycle; 2007 Feb; 6(4):418-29. PubMed ID: 17329972
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor-dependent cell cycle progression is altered in mammary epithelial cells that overexpress c-myc.
Nass SJ; Dickson RB
Clin Cancer Res; 1998 Jul; 4(7):1813-22. PubMed ID: 9676860
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.
Shen L; O'Shea JM; Kaadige MR; Cunha S; Wilde BR; Cohen AL; Welm AL; Ayer DE
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5425-30. PubMed ID: 25870263
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer.
Li B; Simon MC
Clin Cancer Res; 2013 Nov; 19(21):5835-41. PubMed ID: 23897900
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence.
Leung JY; Andrechek ER; Cardiff RD; Nevins JR
Oncogene; 2012 May; 31(20):2545-54. PubMed ID: 21996730
[TBL] [Abstract][Full Text] [Related]
19. Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.
Shao P; Liu Q; Maina PK; Cui J; Bair TB; Li T; Umesalma S; Zhang W; Qi HH
Nucleic Acids Res; 2017 Feb; 45(4):1687-1702. PubMed ID: 27899639
[TBL] [Abstract][Full Text] [Related]
20. p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value.
Santoro A; Vlachou T; Luzi L; Melloni G; Mazzarella L; D'Elia E; Aobuli X; Pasi CE; Reavie L; Bonetti P; Punzi S; Casoli L; Sabò A; Moroni MC; Dellino GI; Amati B; Nicassio F; Lanfrancone L; Pelicci PG
Cell Rep; 2019 Jan; 26(3):624-638.e8. PubMed ID: 30650356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
